Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

Af­ter 24 years with­out con­firm­ing clin­i­cal ben­e­fit, the FDA an­nounced Tues­day morn­ing that Vi­a­tris (formed via My­lan and Pfiz­er’s Up­john) has de­cid­ed to with­draw a top­i­cal an­timi­cro­bial agent, Sul­famy­lon (mafenide ac­etate), af­ter the com­pa­ny said con­duct­ing a con­fir­ma­to­ry study was not fea­si­ble.

Sul­famy­lon first won FDA’s ac­cel­er­at­ed nod in 1998 as a top­i­cal burn treat­ment, with the FDA not­ing that last De­cem­ber, My­lan told the agency that it wasn’t run­ning the tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER